Benjamin Edwards’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.93M Sell
2,539
-74
-3% -$55.9K 0.02% 582
2026
Q2
$1.63M Buy
2,613
+560
+27% +$381K 0.01% 636
2026
Q1
$1.59M Sell
2,053
-2,251
-52% -$1.72M 0.02% 613
2025
Q4
$3.32M Sell
4,304
-132
-3% -$89.6K 0.04% 388
2025
Q3
$2.49M Buy
4,436
+559
+14% +$316K 0.03% 444
2025
Q2
$2.04M Buy
3,877
+1,922
+98% +$1.07M 0.03% 455
2025
Q1
$1.24M Buy
1,955
+307
+19% +$211K 0.02% 522
2024
Q4
$1.17M Sell
1,648
-1,489
-47% -$1.25M 0.02% 559
2024
Q3
$3.3M Buy
3,137
+3,112
+12,448% +$3.46M 0.05% 337
2024
Q2
$26K Buy
25
+4
+19% +$3.88K 0.01% 568
2024
Q1
$20K Buy
+21
New +$20K ﹤0.01% 575
2023
Q4
– Sell
-5
Closed -$4K – 662
2023
Q3
$4K Hold
5
– – ﹤0.01% 608
2023
Q2
$4K Hold
5
– – ﹤0.01% 625
2023
Q1
$4K Hold
5
– – ﹤0.01% 643
2022
Q4
$4K Sell
5
-33
-87% -$24.3K ﹤0.01% 648
2022
Q3
$26K Hold
38
– – 0.01% 487
2022
Q2
$22K Hold
38
– – 0.01% 511
2022
Q1
$27K Sell
38
-15
-28% -$9.49K 0.01% 524
2021
Q4
$33K Buy
+53
New +$32.6K 0.01% 463
2021
Q2
– Sell
-31
Closed -$15K – 438
2021
Q1
$15K Buy
+31
New +$15.1K 0.01% 322

Other funds holding REGN

Benjamin Edwards's REGN Position: Q3 2026 in Review

Benjamin Edwards reduced its Regeneron Pharmaceuticals (REGN) stake by 2.8% in Q3 2026, selling an estimated $55.9K and leaving 2,539 shares worth $1.93M. The position accounts for 0.02% of the portfolio, ranked #582.

Benjamin Edwards first reported a position in REGN in Q1 2021 and has held it in 20 quarters since. The position peaked at $3.32M in Q4 2025. 1,212 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

  • Benjamin Edwards held 2,539 shares of Regeneron Pharmaceuticals worth $1.93M as of Q3 2026.
  • Benjamin Edwards sold 74 Regeneron Pharmaceuticals shares in Q3 2026, an estimated $55.9K.
  • Regeneron Pharmaceuticals made up 0.02% of Benjamin Edwards's portfolio in Q3 2026, its #582 holding.
  • Benjamin Edwards first reported a position in Regeneron Pharmaceuticals in Q1 2021 and has held it in 20 quarters since.
  • Benjamin Edwards's Regeneron Pharmaceuticals position peaked at $3.32M in Q4 2025.
  • 1,212 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Benjamin Edwards's 13F filing for Q3 2026, filed 12 Nov 2026.